Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.7K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.7K
Essential Minerals for Bone Health01:31

Essential Minerals for Bone Health

5.7K
The minerals contained in all of the food we consume are essential for our organ systems. However, certain essential minerals, such as calcium, phosphorus, magnesium, manganese, and fluoride, largely affect bone health.
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
5.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

1.0K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
1.0K
Bone Disorders01:29

Bone Disorders

5.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
5.0K
Bone Remodeling01:40

Bone Remodeling

40.1K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of 3D-DXA-derived proximal femur measurements against QCT across international clinical cohorts.

Bone·2026
Same author

Monte Carlo Resampling Validates Use of Bone Mineral Density Change as Surrogate to Replace Fracture in Future Randomized Trials of Osteoporosis Treatments: Results From SABER.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Response to Letter to the Editor regarding "The relationship between treatment-related changes in total hip BMD measured after 12, 18, and 24 mo and fracture risk reduction in osteoporosis clinical trials: the FNIH-ASBMR-SABRE project".

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

The 2024 UK clinical guideline for the prevention and treatment of osteoporosis.

Archives of osteoporosis·2025
Same author

External validation of FRISBEE 2-year and 5-year fracture prediction models in a fracture liaison service cohort.

Archives of osteoporosis·2025
Same author

Treatment-related changes in total hip bone mineral density are applicable to trials of varied study designs and to drugs with differing mechanisms of action: meta-regression results from the FNIH-ASBMR SABRE study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2025
Same journal

Baseline β-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12 months in postmenopausal Indian women with osteoporosis.

Bone·2026
Same journal

Bone density-based maturation of the midpalatal suture in children aged 8-15 years.

Bone·2026
Same journal

Disrupted phosphate metabolism and SIBLING/ASARM peptide accumulation underlie impaired bone mineralization in klotho-deficient (kl/kl) mice.

Bone·2026
Same journal

Linking genetic variants to bone microstructure: Histological signatures of osteogenesis imperfecta subtypes.

Bone·2026
Same journal

The impact of alcohol consumption on bone mineral density: Insights from cross-sectional and Mendelian randomization studies.

Bone·2026
Same journal

Systemic and local predictors of medication-related osteonecrosis of the jaw in patients receiving antiresorptive therapy: The Shizuoka Kokuho Database study.

Bone·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.2K

Zoledronate.

Ian R Reid1, Jonathan R Green2, Kenneth W Lyles3

  • 1Department of Medicine, University of Auckland, Auckland, New Zealand.

Bone
|May 1, 2020
PubMed
Summary
This summary is machine-generated.

Zoledronate is a potent bisphosphonate for osteoporosis and Paget's disease, offering fracture prevention. Further research is needed to confirm its potential benefits in reducing cancer, cardiovascular disease, and mortality.

Keywords:
BisphosphonatesOsteopeniaOsteoporosisPaget's disease

More Related Videos

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.6K
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.9K

Related Experiment Videos

Last Updated: Dec 22, 2025

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

28.2K
Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
08:53

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model

Published on: January 1, 2017

9.6K
Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis
08:13

Microwave-driven Synthesis of Iron Oxide Nanoparticles for Fast Detection of Atherosclerosis

Published on: March 22, 2016

10.9K

Area of Science:

  • Pharmacology
  • Bone Metabolism
  • Oncology

Background:

  • Zoledronate is a potent, long-acting bisphosphonate administered intravenously.
  • It is widely used for osteoporosis, Paget's disease, and to mitigate skeletal-related events in cancer patients.

Purpose of the Study:

  • To review the efficacy and safety of zoledronate in treating bone diseases.
  • To explore potential non-skeletal benefits and limitations of zoledronate therapy.

Main Methods:

  • Review of clinical trial data and observational studies on zoledronate.
  • Analysis of efficacy in fracture prevention, Paget's disease remission, and potential effects on mortality, cardiovascular disease, and cancer.

Main Results:

  • Zoledronate demonstrates comparable anti-fracture efficacy to denosumab in osteoporosis and superior remission rates in Paget's disease.
  • Potential benefits in reducing mortality, cardiovascular disease, and cancer are suggested but not consistently proven.
  • Nephrotoxicity and hypocalcemia are key safety concerns, requiring renal function and vitamin D assessment.
  • The acute phase response is a common, transient side effect; osteonecrosis of the jaw and atypical femoral fractures are not increased in clinical trials.

Conclusions:

  • Zoledronate is a cost-effective treatment for fracture prevention and Paget's disease management.
  • Improved access to infusion facilities is crucial for wider patient benefit.
  • Further investigation into zoledronate's potential non-skeletal effects is warranted due to their significant implications.